Contract

Associate Director

PBM/Payer Contract Strategy and Analytics

Posted on 8/7/2025

Deadline 10/11/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$152.9k - $185.3k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Hybrid

Hybrid work model with at least 50% onsite presence required.

Category
Finance & Banking (1)
Required Skills
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • BA/BS degree
  • A minimum of 5 years of experience in the pharmaceutical/healthcare industry is strongly advised
  • Strong technical/functional skills and an ability to motivate, develop, and lead others as a player/coach
  • Experience in negotiating, executing, and implementing contracts
  • Strong analytical skills and ability to think strategically about the impact of various contracting approaches which could be employed in a complex ecosystem/marketplace
  • Firm understanding of the healthcare marketplace and demonstrate strong business acumen, including a solid understanding of the way various channels and customer types make money and create value
  • Demonstrated ability to work across boundaries to partner, influence and build consensus with various stakeholders and Sr. Management in order to get results
  • Proven ability to think and act strategically and to influence others with well thought out and professionally communicated positions and recommendations
  • Exceptional aptitude for learning quickly and ability to communicate technical concepts to a wide range of stakeholders
  • Must demonstrate an ability to drive execution of key initiatives and meet all deadlines
  • Must have a strong ability to prioritize and work effectively in a fast-paced, dynamic environment
  • Track record of highly ethical and compliant behavior
  • Extensive knowledge of BMS products and therapeutic areas or an ability to learn quickly
  • Intellectual Curiosity
  • Capability to take complex analytics and provide executive summary level insights
  • Demonstrated ability to dissect complex problems and recommend solutions
  • Proven ability to embrace new technologies
  • Must have strong oral and written communication skills
  • Proficient in PowerPoint and Excel
Responsibilities
  • Conducts sophisticated analyses with consideration of the BMS and the customers’ perspective of contracted versus non-contracted revenue and works closely with the NAE and integrated customer team to evaluate appropriate options and strategies for leveraging additional value creating opportunities
  • Lead cross-matrix meetings with Brand Marketing, Access Strategy, Pricing Strategy, Finance and NAE to present and gain approval for contract offer recommendations that balance customer needs with brand objectives to ensure deals represent the best interests of all parties
  • Provides direct customer-facing support for the NAE and integrated customer team in contract negotiations, including developing and presenting supporting information that enhances negotiation discussions such as detailed offer analytics
  • Presents Situation, deal Analytics and Contract Recommendations to Brand Business Unit Lead decision makers as part of the Negotiating Team process
  • Monitors the competition, marketplace, and regulatory changes that could influence contract terms
  • Utilize knowledge of channel/customer economics to negotiate contract language to drive value for customer and BMS
  • Works in partnership with the Brand, Finance, Pricing Strategy and Access Strategy on customer-specific rebate projections
  • Works with internal government and legal experts to monitor the latest government contracting and reporting requirements, and ensures government pricing implications are identified and considered
  • Utilizes sophisticated analytical techniques to analyze and monitor customer compliance and performance against contract terms and keeps the NAE informed on an ongoing and regular basis
  • Understands inter-customer dynamics and the commercial implications for structuring deal negotiations
  • Provides proactive insights and recommendations to the NAE to deliver stronger value for the customer and BMS
  • Acts as a liaison with the brand team, on behalf of the NAE, to ensure all contracts are structured to be consistent with brand strategy and to maximize value creation for all stakeholders
  • Works with counterparts to ensure pricing strategies/philosophy can be executed within BMS’ contracting requirements
  • Works with Legal throughout contract negotiation with the customer to ensure contracts are legally compliant and best protect the interests of BMS
  • Acts as leader amongst their peers on CSA team to coach and train Sr. Managers technical/functional skills & working with matrix team members and customers
  • Strong problem solving skills, an aptitude for efficient communication across matrix partners and in-depth business analyses is critical to this role
Desired Qualifications
  • Advanced degree (e.g., master’s degree in Finance/MBA, Health Administration) is preferred
  • Headquarters and cross-functional experience is a plus (e.g., product marketing, business development, sales, Finance, PASS etc.)
  • Market Access or relevant consultancy experience, Payer or health System provider experience is preferred
  • Demonstrated experience leveraging and/or implementing, AI-driven insights and digital tools to enhance customer engagement strategies, optimize HCP/patient experience, and drive data-informed commercial decision-making

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE